Long-Term Effects of Fingolimod in Multiple Sclerosis: The Randomized FREEDOMS Extension Trial

Neurology - United States
doi 10.1212/wnl.0000000000001462
Full Text
Abstract

Available in full text

Categories
Neurology
Date
Authors
Publisher

Ovid Technologies (Wolters Kluwer Health)

Related search

Long-Term Effect of Immediate Versus Delayed Fingolimod Treatment in Young Adult Patients With Relapsing–Remitting Multiple Sclerosis: Pooled Analysis From the FREEDOMS/FREEDOMS II Trials

Neurology and Therapy
Neurology
2019English

Long-Term Safety and Real-World Effectiveness of Fingolimod in Relapsing Multiple Sclerosis

Patient Related Outcome Measures
2017English

Correction To: Long-Term Effect of Immediate Versus Delayed Fingolimod Treatment in Young Adult Patients With Relapsing–Remitting Multiple Sclerosis: Pooled Analysis From the FREEDOMS/FREEDOMSII Trials

Neurology and Therapy
Neurology
2020English

Long-Term Evaluation of NEDA-3 Status in Relapsing-Remitting Multiple Sclerosis Patients After Switching From Natalizumab to Fingolimod

Therapeutic Advances in Neurological Disorders
NeurologyPharmacology
2018English

Tumefactive Multiple Sclerosis Lesions Under Fingolimod Treatment

Neurology
Neurology
2012English

Myeloid Cells as Target of Fingolimod Action in Multiple Sclerosis

Neurology: Neuroimmunology and NeuroInflammation
Neurology
2015English

Long Term Consequences of Arsenical Treatment for Multiple Sclerosis.

BMJ
1983English

Natalizumab Versus Fingolimod and Dimethyl Fumarate in Multiple Sclerosis Treatment

Annals of Clinical and Translational Neurology
NeuroscienceNeurology
2018English

Long‐Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52‐Week Extension Trial

Headache
Neurology
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy